Cancer complicating systemic lupus erythematosus - A dichotomy emerging from a nested case-control study

Lupus

Volumn 22, Issue 9, 2013, Pages 919-927

  Dey, D ^a   Kenu, E ^b   Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b KORLE BU TEACHING HOSPITAL   (Ghana)

Author keywords

immunosuppressive therapy; neoplasm; risk factors; Systemic lupus erythematosus (SLE)

Indexed keywords

ADULT; AGED; ANUS CANCER; APPENDIX CANCER; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE CANCER; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LUNG CANCER; MALE; MEDICAL RECORD REVIEW; NEOPLASM; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SKIN CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; TONGUE CANCER; UTERINE CERVIX CANCER; VULVA CANCER; ADOLESCENT; CASE CONTROL STUDY; CHILD; COMPLICATION; INCIDENCE; INFANT; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; YOUNG ADULT;

EID: 84880854982     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313497118     Document Type: Article

References (47)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003 ; 82: 299-308
2. Ward M, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum. 1995 ; 38: 1492-1499
3. Moss K, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 ; 61: 409-413
4. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995 ; 24: 1061-1065
5. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011 ; 7: 360-368
6. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992 ; 51: 437-439
7. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Invest Med. 1998 ; 46: 217-222
8. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Jorgen HO. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 761-768
9. Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol. 1995 ; 22: 1478-1482
10. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 1050-1054
11. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005 ; 52: 1481-1490
12. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. The Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol. 1991 ; 18: 809-814
13. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis. 1988 ; 47: 988-992
14. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet. 1995 ; 346: 403-406
15. Mariette X. Lymphomas in patients with Sjögren's syndrome: Review of the literature and physiopathologic hypothesis. Leuk Lymphoma. 1999 ; 33: 93-99
16. Oertel SH, Riess H. Immunosurveillance, immunodeficiency and lymphoproliferation. Recent Results Cancer Res. 2002 ; 159: 1-8
17. Boubenider S, Hiesse C, Groupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997 ; 10: 136-145
18. Bernatsky S, Boivin JF, Joseph L, et al. Prevalence of factors influencing cancer risk in women with lupus: Social habits, reproductive issues, and obesity. J Rheumatol. 2002 ; 29: 2551-2554
19. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2001 ; 27: 750-756
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
21. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 809-813
22. Cancer incidence, prevalence, survival and treatment for residents of South East London in 2008. London: Thames Cancer Registry ; 2010:
23. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC. Sci Publ. 1987 ; 82: 1-406
24. Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002 ; 31: 66-71
25. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus. 2001 ; 10: 394-400
26. Parikh-Patel A, White R, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008 ; 19: 887-894
27. Chen YJ, Chang YT, Wang CB, Wu CY. Malignancy in systemic lupus erythematosus: A nationwide cohort study in Taiwan. Am J Med. 2010 ; 123: 1150.e1-1150.e6
28. Lewis R, Castor CW, Knisley RE, Bole GG. Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1976 ; 19: 1256-1260
29. Bernatsky S, Easton D, Dunning AM, et al. Decreased breast cancer risk in SLE: Can a genetic basis be determined?. Arthritis Rheum. 2011 ; 63: 223-224
30. Bin J, Bernatsky S, Gordon C, et al. Lung cancer in systemic lupus erythematosus. Lung Cancer. 2007 ; 56: 303-306
31. Cancer Research UK. Cancer Statistics key facts, http://www. cancerresearchuk.org/cancerstats (2010).
32. Turner-Warwick M, Lebowitz M, Burrows B, Johnson B. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980 ; 35: 496-499
33. Harris JM, Johnston IDA, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: The BTS study. Thorax. 2010 ; 65: 70-76
34. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000 ; 161: 5-8
35. Bernatsky S, Ramsey-Goldman R, Gordon C, Clarke AE. Prostate cancer in systemic lupus erythematosus. Int J Cancer. 2011 ; 129: 2966-2969
36. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis Rheum. 2005 ; 52: 2740-2750
37. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5-yr prospective study. Rheumatology (Oxford). 2004 ; 43: 1039-1044
38. Chambers S, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009 ; 48: 673-675
39. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006 ; 54: 692-701
40. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: A prospective cohort study. Arthritis Rheum. 2004 ; 50: 1262-1269
41. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006 ; 65: 796-803
42. Turken O, Narin Y, Demirbas S, et al. Breast cancer association with thyroid disorders. Breast Cancer Res. 2003 ; 5: 110-113
43. Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol. 2007 ; 32: 184-187
44. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am. 1996 ; 25: 773-791
45. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review). Oncology Rep. 2005 ; 13: 559-583
46. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993 ; 85: 307-311
47. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2550-2557